2023
Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodes
2020
Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma
Deig C, Stratton A, Trone K, Beneville B, Liu A, Kanwar A, Bassale S, Chen Y, Grossblatt-Wait A, Attia F, Sheppard B, Keith D, Chen E, Lopez C, Billingsley K, Gilbert E, Nabavizadeh N, Thomas C, Grossberg A. Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e606-e607. DOI: 10.1016/j.ijrobp.2020.07.1845.Peer-Reviewed Original Research